Table 3. Economic analysis: patient characteristics and costs.

		TTBI (n = 43)	no TTBI (n = 38)	p
Patient characteristics
Age (years)		62·57 ±6·38	64·72±9·45	0·23
Male/female		28/15	15/23	0·02
Disease duration (years)		7.15±4·48	7·74±4·80	0·61
Number of chronic conditions		1·49± 1.26	2.11±1.59	0·08
UPDRS II changes		-1.21±3.16	1.18±4.03	<0.01
UPDRS III changes		-0.84±5.09	2.00±6.80	0.01
Mean annual costs per patient (Euros)
Hospitalization		1715±5,651	1550±2380	0·34
Ambulatory care		1539±1,830	1746±1790	0·44
Medical visits		350±176	374±192	0·74
Medical actsa		143±147	189±145	0·08
Laboratory tests		58±56	104±114	0·05
Paramedical actsb		792±1,734	934±1,674	0·72
Othersc		196±420	146±202	0·23
Treatments		3693±5,164	3924±6076	0·68
Drugs		3.064±5,164	3296±2847	0·67
Antiparkinsonian drugs		2427±2,009	2590±2576	0·95
Psychotropic drugd		76±137	145±236	0·12
Other drugs		563±540	570±643	0·69
Medical equipmente		629±3,511	627±3529	0·36
Transportation		126±448	227±375	0·07
Education program		250	-	-
Total costs		7323±8560	7372±8022	0·50
Incremental cost-effectiveness ratios
	Incremental cost (€)	Incremental effectiveness	Observed ICERf	Simulated boostrap ICER (95%)CIg
UPDRS II score	-49	-2.39	-21	9 (-1,738; + 2,515)
UPDRS III score	-49	-2.84	-17	-19 (-1,898; + 2,506)

Values are means±SD

^a: Diagnostic and therapeutic acts

^b: performed by a nurse, physiotherapist, orthoptist or speech therapist

^c: dental acts, spa therapy

^d: antipsychotic drugs, antidepressants, benzodiazepines, non-benzodiazepine hypnotic drugs

^e: respiratory assistance, apomorphine pump, orthosis

^f: ICER is expressed as € per one point improvement in UPDRS II & III

^g: results of non-parametric boostrap ICER is presented as median and 95%. CI